miR‑125b suppresses cellular proliferation by targeting c‑FLIP in gallbladder carcinoma

Zong,Huajie; Zhou,Huading; Xiang,Yang; Wu,Gang

doi:10.3892/ol.2019.11000

miR‑125b suppresses cellular proliferation by targeting c‑FLIP in gallbladder carcinoma

Authors:
- Huajie Zong
- Huading Zhou
- Yang Xiang
- Gang Wu
View Affiliations

Affiliations: Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: October 18, 2019 https://doi.org/10.3892/ol.2019.11000
Pages: 6822-6828

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallbladder carcinoma (GBC) is the most common malignant tumor of the biliary tract. The incidence rate of gallbladder cancer ranks sixth among gastrointestinal types of cancer, and its incidence is increasing each year. Further clarification of the pathogenesis of GBC is essential, and identification of novel effective treatments is required. It has been previously demonstrated that high expression of the anti‑apoptotic protein cellular Fas‑associated death domain‑like interleukin‑1‑converting enzyme inhibitory protein (c‑FLIP) in GBC inhibited apoptosis in gallbladder cancer cells. In subsequent experiments, it was observed that microRNA (miR)‑125b could target c‑FLIP and inhibit the protein expression of c‑FLIP by binding to the 3'untranslated regions of c‑FLIP mRNA. In addition, the expression of miR‑125b in GBC was significantly decreased, and the growth of gallbladder cancer cells was inhibited by the overexpression of miR‑125b. The present study demonstrated that miR‑125b could suppress the proliferation of gallbladder cancer cells by targeting c‑FLIP. c‑FLIP enriched the target gene pathway of miR‑125b and may serve as a novel target for the treatment of GBC.

View Figures

View References

1	Chen YL, Huang ZQ, Zhou NX, Zhang WZ, Huang XQ, Duan WD, Liu R and Liu Y: Clinical analysis of 110 patients with primary gallbladder carcinoma. Zhonghua Zhong Liu Za Zhi. 29:704–706. 2007.(In Chinese). PubMed/NCBI
2	de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med. 341:1368–1378. 1999. View Article : Google Scholar : PubMed/NCBI
3	Ashkenazi A: Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 19:325–331. 2008. View Article : Google Scholar : PubMed/NCBI
4	Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I, Scliri M, Bousboukea K, Michalopoulos NV, Apostolikas N, et al: c-FLIP expression in colorectal carcinomas: Association with Fas/FasL expression and prognostic implications. Histopathology. 51:150–156. 2007. View Article : Google Scholar : PubMed/NCBI
5	Zhang X, Li W and Olumi AF: Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP. Methods Enzymol. 446:333–349. 2008. View Article : Google Scholar : PubMed/NCBI
6	Haag C, Stadel D, Zhou S, Bachem MG, Moller P, Debatin KM and Fulda S: Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut. 60:225–237. 2011. View Article : Google Scholar : PubMed/NCBI
7	Tian F, Lu JJ, Wang L, Li L, Yang J, Li Y, Liu YQ, Shen GX, Tu YT and Tao J: Expression of c-FLIP in malignant melanoma, and its relationship with the clinicopathological features of the disease. Clin Exp Dermatol. 37:259–265. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zong H, Yin B, Chen J, Ma B, Cai D and He X: Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J Exp Med. 217:203–208. 2009. View Article : Google Scholar : PubMed/NCBI
9	Shirley S and Micheau O: Targeting c-FLIP in cancer. Cancer Lett. 332:141–150. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
11	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
12	Chen F, Zhu HH, Zhou LF, Wu SS, Wang J and Chen Z: Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep. 23:1457–1462. 2010. View Article : Google Scholar : PubMed/NCBI
13	Jia K, Shi P, Han X, Chen T, Tang H and Wang J: Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction. Mol Med Rep. 14:184–194. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wang XL, Zhao YY, Sun L, Shi Y, Li ZQ, Zhao XD, Xu CG, Ji HG, Wang M, Xu WR and Zhu W: Exosomes derived from human umbilical cord mesenchymal stem cells improve myocardial repair via upregulation of Smad7. Int J Mol Med. 41:3063–3072. 2018.PubMed/NCBI
15	Benoist S, Panis Y and Fagniez PL: Long-term results after curative resection for carcinoma of the gallbladder. French University Association for Surgical Research. Am J Surg. 175:118–122. 1998. View Article : Google Scholar : PubMed/NCBI
16	Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J Surg. 196:252–264. 2008. View Article : Google Scholar : PubMed/NCBI
17	Misra S, Chaturvedi A, Misra NC and Sharma ID: Carcinoma of the gallbladder. Lancet Oncol. 4:167–176. 2003. View Article : Google Scholar : PubMed/NCBI
18	Saetta AA: K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer. J Surg Oncol. 93:644–649. 2006. View Article : Google Scholar : PubMed/NCBI
19	Takagawa M, Muguruma N, Oguri K, Imoto Y, Okamoto K, Ii K and Ito S: Prediction of prognosis in gallbladder carcinoma by mucin and p53 immunohistochemistry. Dig Dis Sci. 50:1410–1413. 2005. View Article : Google Scholar : PubMed/NCBI
20	Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A and Koyanagi Y: Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg. 7:198–205. 2000. View Article : Google Scholar : PubMed/NCBI
21	Wang BL, Zhai HY, Chen BY, Zhai SP, Yang HY, Chen XP, Zhao WT and Meng L: Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat Dis Int. 3:296–299. 2004.PubMed/NCBI
22	Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P and Fuchs CS: Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 53:564–570. 2008. View Article : Google Scholar : PubMed/NCBI
23	Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D and Javle MM: A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: A single-institution prospective study. Ann Surg Oncol. 14:3202–3209. 2007. View Article : Google Scholar : PubMed/NCBI
24	Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY and Kang WK: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol. 60:321–328. 2007. View Article : Google Scholar : PubMed/NCBI
25	Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, et al: Inhibition of death receptor signals by cellular FLIP. Nature. 388:190–195. 1997. View Article : Google Scholar : PubMed/NCBI
26	Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R and Olumi AF: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 64:7086–7091. 2004. View Article : Google Scholar : PubMed/NCBI
27	Safa AR: c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 34:176–184. 2012.PubMed/NCBI
28	McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, O'Sullivan JM, Longley DB and Waugh DJ: Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res. 18:3822–3833. 2012. View Article : Google Scholar : PubMed/NCBI
29	Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schon MP, Henkler F, Gollnick H, Walczak H and Leverkus M: Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL-and CD95L-mediated apoptosis. Oncogene. 27:3211–3220. 2008. View Article : Google Scholar : PubMed/NCBI
30	White SJ, Lu P, Keller GM and Voelkel-Johnson C: Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biol Ther. 5:1618–1623. 2006. View Article : Google Scholar : PubMed/NCBI
31	Du X, Bao G, He X, Zhao H, Yu F, Qiao Q, Lu J and Ma Q: Expression and biological significance of c-FLIP in human hepatocellular carcinomas. J Exp Clin Cancer Res. 28:242009. View Article : Google Scholar : PubMed/NCBI
32	Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L and Johnston PG: c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene. 25:838–848. 2006. View Article : Google Scholar : PubMed/NCBI
33	Luo A, Wang W, Sima N, Lu Y, Zhou J, Xu G, Yu H, Wang S and Ma D: Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy. Cancer Lett. 271:323–332. 2008. View Article : Google Scholar : PubMed/NCBI
34	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
35	Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003. View Article : Google Scholar : PubMed/NCBI
36	Sun YM, Lin KY and Chen YQ: Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol. 6:62013. View Article : Google Scholar : PubMed/NCBI
37	Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, Fu Z and You Y: MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 1312:120–126. 2010. View Article : Google Scholar : PubMed/NCBI
38	Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, et al: Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 123:1616–1622. 2008. View Article : Google Scholar : PubMed/NCBI
39	Kappelmann M, Kuphal S, Meister G, Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene. 32:2984–2991. 2013. View Article : Google Scholar : PubMed/NCBI
40	Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Kuwano H and Mori M: MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol. 38:1437–1443. 2011.PubMed/NCBI
41	Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, et al: Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 21:4234–4242. 2015. View Article : Google Scholar : PubMed/NCBI
42	Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D and Aguiar RC: MicroRNAs miR-125a and miR-125b constitutively activate the NF-KB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA. 109:7865–7870. 2012. View Article : Google Scholar : PubMed/NCBI